- Home
- OGEN vs BREA Comparison
OGEN vs BREA Comparison
Compare OGEN & BREA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- BREA
- Stock Information
- Founded
- OGEN 1996
- BREA 2022
- Country
- OGEN United States
- BREA Ireland
- Employees
- OGEN N/A
- BREA N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- BREA Services-Misc. Amusement & Recreation
- Sector
- OGEN Health Care
- BREA Consumer Discretionary
- Exchange
- OGEN Nasdaq
- BREA Nasdaq
- Market Cap
- OGEN 2.5M
- BREA 13.6M
- IPO Year
- OGEN N/A
- BREA 2023
- Fundamental
- Price
- OGEN $1.50
- BREA $7.55
- Analyst Decision
- OGEN
- BREA
- Analyst Count
- OGEN 0
- BREA 0
- Target Price
- OGEN N/A
- BREA N/A
- AVG Volume (30 Days)
- OGEN 1.1M
- BREA 18.1K
- Earning Date
- OGEN 08-08-2025
- BREA 01-01-0001
- Dividend Yield
- OGEN N/A
- BREA N/A
- EPS Growth
- OGEN N/A
- BREA N/A
- EPS
- OGEN N/A
- BREA N/A
- Revenue
- OGEN N/A
- BREA $2,988,009.00
- Revenue This Year
- OGEN N/A
- BREA N/A
- Revenue Next Year
- OGEN N/A
- BREA N/A
- P/E Ratio
- OGEN N/A
- BREA N/A
- Revenue Growth
- OGEN N/A
- BREA 151.51
- 52 Week Low
- OGEN $1.35
- BREA $5.00
- 52 Week High
- OGEN $75.60
- BREA $19.50
- Technical
- Relative Strength Index (RSI)
- OGEN 27.35
- BREA 58.43
- Support Level
- OGEN $1.35
- BREA $5.90
- Resistance Level
- OGEN $4.19
- BREA $7.78
- Average True Range (ATR)
- OGEN 0.43
- BREA 0.68
- MACD
- OGEN -0.22
- BREA 0.07
- Stochastic Oscillator
- OGEN 5.14
- BREA 91.00
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.